BCKDHA

Across TCGA pan-cancer cohorts, BCKDHA Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCKDHA data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher BCKDHA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCKDHA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, SKCM, and UCEC are the cancer types where BCKDHA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
SKCM	OS	Median	II,III,IV	0.360	0.735	.044	3	view →
UCEC	DFS	Median	II,III,IV	0.906	0.441	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCKDHA–STAD (DFS)

Open the STAD breakdown →